EIC ePitching on COVID-19: Seven EIC Innovators pitch solutions to help tackle COVID-19
On 15 April 2020 12.00-2.00 pm (CET) seven EIC-funded SMEs will pitch their COVID-related innovations to investors from Capricorn Ventures, Clinical Research Ventures, Diffusion Capital Partners, the European Investment Bank, Idacapital, Illumina Ventures, Panakes Partners and Monte Carlo Capital.
Join the ePitching on COVID-19 following this link.
15 April 2020 12.00-2.00 pm (CET)
In response to the current pandemic, the EIC created a special COVID-group on the EIC Community to gather ideas, innovations and products that might be of use in this period. In response to the overwhelming attention and innovative solutions that were being proposed, the EIC decided to host a special ePitching session dedicated to SMEs with COVID-related innovations and solutions that are looking for investment. A range of very diverse and highly innovative EIC SMEs have been selected to pitch their innovation.
Cellply, based in Italy, develops innovative life science tools to improve patient care supporting fast development of new, effective and personalized therapies. The COVID-19 emergency poses the need to make novel platforms available to scientists to let them dramatically accelerate the development of countermeasures against this and possible future pandemics.
Iceland’s EpiEndo Pharmacauticals has been developing its Barriolides since it was founded in January 2014. Barriolides are 15-membered macrolides (like Azithromycin, AZM) with no antibacterial activity. The design behind the Barriolides is to keep all other desired properties of Azithromycin such as pro-epithelial, anti-inflammatory and anti-viral. Since AZM has suddenly been brought into the spotlight as a potential therapeutic agent against COVID-19, EpiEndo felt it being of utmost importance to notify authorities about the existence of its Barriolides development.
EpiGuard was founded in 2015 in Norway by a group of doctors, engineers and specialist in protective equipment. They hold top level expertise in product development and manufacturing. Their main product, the EpiShuttle, is the preferred solution for protecting the environment during transport of patients with contagious diseases and the need of intensive care.
OTR3 is a French company specialized in therapeutic agents based on proprietary RGTA® (ReGeneraTing Agents) technology which heal lesions by restoring the extracellular matrix and cellular micro-environment. OTR3 is currently developing a new drug , OTR-4120V, based on the proprietary technology of ReGeneraTing Agents (RGTA), that might have the advantage of a double therapeutic action: 1. as host target, in reducing lung inflammation and fibrosis, optimizing pulmonary tissues reparation and regeneration and improving lung function in COVID – 19 patients, 2. as a virus inhibitor that treats the specific virus.
Israeli’s Respinova Ltd. has developed a novel device, PulseHaler™, to treat Chronic obstructive pulmonary disease (COPD) by opening the small airways, which are known to collapse in COPD. PulseHaler™ was shown clinically to substantially improve the functional capabilities and quality of life of COPD patients. Now they want to use their Pulsehaler to treat COVID-19 patients.
Prevention is better than cure, that is motto of UK-based Smart Separations. Their filtration system was designed to bring better air quality to everyone. In addition, their coating now has a unique opportunity in cleansing air, surfaces and products to avoid the spread of COVID-19 and other viruses, saving thousands of lives. Their coatings have shown to operate even after washing many times, meaning it is highly durable.
Using their experience to create rapid on-site tests for bacteria and viruses, SwissDeCode has created a test for COVID-19. They are currently working with university hospitals in Switzerland to conduct human trials. They are also preparing for the future when our food supply chains have to be COVID-19 free.
Considering applying next time? As a member of the EIC Community, you will be able to follow the e-pitching session and watch the companies selected by the investors within the EIC ScaleUp EU tool presenting their business cases. Just join us following this link on 15 April, from 12:00 to 2:00 pm (CET).
The EIC ePitching sessions are a regular part of the European Innovation Council Business Acceleration Services. For the month of April 2020 we have planned another Epitch on eHealth. Keep your eyes on our EIC Community for further ePitching sessions in May and June 2020!
For any questions please do not hesitate to contact us through our contact page (choose ‘Request access to the Investor matching tool “Scaleup”’).